Pneumonia Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product (Branded Drugs, Generic Drugs, Vaccines, and Others); Indication Type (Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), and Ventilator-Associated Pneumonia (VAP)); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Geography

Report Code: TIPRE00021595 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET INTRODUCTION

Pneumonia is a term used to describe a disorder that affects the alveoli of the lungs. Pneumonia is caused by bacteria, fungi, or viruses, and is responsible for 5-6% of all deaths in children under the age of five. In the pediatric population of African nations, the prevalence of pneumonia is substantially high. Due to high rate of morbidity and mortality associated with pneumococcal infection and rise in the number of resistant strains, pneumonia preventive therapy has become common. The vaccines' high preventive rates, 5-year immunization plan, and increasing regulatory support for vaccination are expected to provide lucrative growth opportunities.
MARKET DYNAMIC
Factors driving the growth of the pneumonia therapeutics market are growing number of ongoing clinical trials for vaccine development and drug molecules, and surging cases of pneumonia across the globe. However, low treatment rates in developing economies is likely to hamper the growth of the market. Moreover, increasing funding opportunities in R&D for new product development is likely to create growth opportunities in the market.

MARKET SCOPE

The "Pneumonia Therapeutics Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of pneumonia therapeutics market with detailed market segmentation by product, indication type, and distribution channel. The pneumonia therapeutics market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in pneumonia therapeutics market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The pneumonia therapeutics market is segmented based on product, indication type, and distribution channel. Based on product, the market is categorized as branded drugs, generic drugs, vaccines, and others. The branded drugs market is further segmented into aminopenicillins, carbapenems, quinolones, macrolides, B-lactamase inhibitors, tetracyclines, cephalosporins, glycopeptide antibiotics, and others. The generic drugs market is further segmented into quinolones, macrolides, and others. Based on indication type, the market is categorized as hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and ventilator-associated pneumonia (VAP). Based on distribution channel, the market is categorized as hospital pharmacies, retail pharmacies, and online pharmacies.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the pneumonia therapeutics market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The pneumonia therapeutics market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting pneumonia therapeutics market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the pneumonia therapeutics market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the pneumonia therapeutics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from pneumonia therapeutics market are anticipated to have lucrative growth opportunities in the future with the rising demand for pneumonia therapeutics in the global market. Below mentioned is the list of few companies engaged in the pneumonia therapeutics market.

The report also includes the profiles of key players in pneumonia therapeutics market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, products and services offered, financial information of last 3 years, key development in past five years.

  •   Pfizer, Inc.
  •   Merck & Co., Inc.
  •   GlaxoSmithKline Plc
  •   Bayer AG
  •   Novartis AG
  •   Allergan
  •   Lupin Pharmaceuticals, Inc.
  •   Smith & Nephew
  •   Abbott
  •   Cipla

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Pneumonia Therapeutics Market - By Product
1.3.2 Pneumonia Therapeutics Market - By Indication Type
1.3.3 Pneumonia Therapeutics Market - By Distribution Channel
1.3.4 Pneumonia Therapeutics Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PNEUMONIA THERAPEUTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PNEUMONIA THERAPEUTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PNEUMONIA THERAPEUTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. PNEUMONIA THERAPEUTICS - GLOBAL MARKET OVERVIEW
6.2. PNEUMONIA THERAPEUTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. PNEUMONIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. BRANDED DRUGS
7.3.1. Overview
7.3.2. Branded Drugs Market Forecast and Analysis
7.3.3. Quinolones Market
7.3.3.1. Overview
7.3.3.2. Quinolones Market Forecast and Analysis
7.3.4. Aminopenicillins Market
7.3.4.1. Overview
7.3.4.2. Aminopenicillins Market Forecast and Analysis
7.3.5. Macrolides Market
7.3.5.1. Overview
7.3.5.2. Macrolides Market Forecast and Analysis
7.3.6. B-Lactamase Inhibitors Market
7.3.6.1. Overview
7.3.6.2. B-Lactamase Inhibitors Market Forecast and Analysis
7.3.7. Cephalosporins Market
7.3.7.1. Overview
7.3.7.2. Cephalosporins Market Forecast and Analysis
7.3.8. Tetracyclines Market
7.3.8.1. Overview
7.3.8.2. Tetracyclines Market Forecast and Analysis
7.3.9. Glycopeptide Antibiotics Market
7.3.9.1. Overview
7.3.9.2. Glycopeptide Antibiotics Market Forecast and Analysis
7.3.10. Carbapenems Market
7.3.10.1. Overview
7.3.10.2. Carbapenems Market Forecast and Analysis
7.3.11. Others Market
7.3.11.1. Overview
7.3.11.2. Others Market Forecast and Analysis
7.4. GENERIC DRUGS
7.4.1. Overview
7.4.2. Generic Drugs Market Forecast and Analysis
7.4.3. Quinolones Market
7.4.3.1. Overview
7.4.3.2. Quinolones Market Forecast and Analysis
7.4.4. Macrolides Market
7.4.4.1. Overview
7.4.4.2. Macrolides Market Forecast and Analysis
7.4.5. Others Market
7.4.5.1. Overview
7.4.5.2. Others Market Forecast and Analysis
7.5. VACCINES
7.5.1. Overview
7.5.2. Vaccines Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. PNEUMONIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - INDICATION TYPE
8.1. OVERVIEW
8.2. INDICATION TYPE MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL-ACQUIRED PNEUMONIA (HAP)
8.3.1. Overview
8.3.2. Hospital-Acquired Pneumonia (HAP) Market Forecast and Analysis
8.4. COMMUNITY-ACQUIRED PNEUMONIA (CAP)
8.4.1. Overview
8.4.2. Community-Acquired Pneumonia (CAP) Market Forecast and Analysis
8.5. VENTILATOR-ASSOCIATED PNEUMONIA (VAP)
8.5.1. Overview
8.5.2. Ventilator-Associated Pneumonia (VAP) Market Forecast and Analysis
9. PNEUMONIA THERAPEUTICS MARKET - REVENUE AND FORECASTS TO 2028 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES
9.5.1. Overview
9.5.2. Online Pharmacies Market Forecast and Analysis
10. PNEUMONIA THERAPEUTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Pneumonia Therapeutics Market Overview
10.1.2 North America Pneumonia Therapeutics Market Forecasts and Analysis
10.1.3 North America Pneumonia Therapeutics Market Forecasts and Analysis - By Product
10.1.4 North America Pneumonia Therapeutics Market Forecasts and Analysis - By Indication Type
10.1.5 North America Pneumonia Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Pneumonia Therapeutics Market Forecasts and Analysis - By Countries
10.1.6.1 United States Pneumonia Therapeutics Market
10.1.6.1.1 United States Pneumonia Therapeutics Market by Product
10.1.6.1.2 United States Pneumonia Therapeutics Market by Indication Type
10.1.6.1.3 United States Pneumonia Therapeutics Market by Distribution Channel
10.1.6.2 Canada Pneumonia Therapeutics Market
10.1.6.2.1 Canada Pneumonia Therapeutics Market by Product
10.1.6.2.2 Canada Pneumonia Therapeutics Market by Indication Type
10.1.6.2.3 Canada Pneumonia Therapeutics Market by Distribution Channel
10.1.6.3 Mexico Pneumonia Therapeutics Market
10.1.6.3.1 Mexico Pneumonia Therapeutics Market by Product
10.1.6.3.2 Mexico Pneumonia Therapeutics Market by Indication Type
10.1.6.3.3 Mexico Pneumonia Therapeutics Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Pneumonia Therapeutics Market Overview
10.2.2 Europe Pneumonia Therapeutics Market Forecasts and Analysis
10.2.3 Europe Pneumonia Therapeutics Market Forecasts and Analysis - By Product
10.2.4 Europe Pneumonia Therapeutics Market Forecasts and Analysis - By Indication Type
10.2.5 Europe Pneumonia Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Pneumonia Therapeutics Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Pneumonia Therapeutics Market
10.2.6.1.1 Germany Pneumonia Therapeutics Market by Product
10.2.6.1.2 Germany Pneumonia Therapeutics Market by Indication Type
10.2.6.1.3 Germany Pneumonia Therapeutics Market by Distribution Channel
10.2.6.2 France Pneumonia Therapeutics Market
10.2.6.2.1 France Pneumonia Therapeutics Market by Product
10.2.6.2.2 France Pneumonia Therapeutics Market by Indication Type
10.2.6.2.3 France Pneumonia Therapeutics Market by Distribution Channel
10.2.6.3 Italy Pneumonia Therapeutics Market
10.2.6.3.1 Italy Pneumonia Therapeutics Market by Product
10.2.6.3.2 Italy Pneumonia Therapeutics Market by Indication Type
10.2.6.3.3 Italy Pneumonia Therapeutics Market by Distribution Channel
10.2.6.4 Spain Pneumonia Therapeutics Market
10.2.6.4.1 Spain Pneumonia Therapeutics Market by Product
10.2.6.4.2 Spain Pneumonia Therapeutics Market by Indication Type
10.2.6.4.3 Spain Pneumonia Therapeutics Market by Distribution Channel
10.2.6.5 United Kingdom Pneumonia Therapeutics Market
10.2.6.5.1 United Kingdom Pneumonia Therapeutics Market by Product
10.2.6.5.2 United Kingdom Pneumonia Therapeutics Market by Indication Type
10.2.6.5.3 United Kingdom Pneumonia Therapeutics Market by Distribution Channel
10.2.6.6 Rest of Europe Pneumonia Therapeutics Market
10.2.6.6.1 Rest of Europe Pneumonia Therapeutics Market by Product
10.2.6.6.2 Rest of Europe Pneumonia Therapeutics Market by Indication Type
10.2.6.6.3 Rest of Europe Pneumonia Therapeutics Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Pneumonia Therapeutics Market Overview
10.3.2 Asia-Pacific Pneumonia Therapeutics Market Forecasts and Analysis
10.3.3 Asia-Pacific Pneumonia Therapeutics Market Forecasts and Analysis - By Product
10.3.4 Asia-Pacific Pneumonia Therapeutics Market Forecasts and Analysis - By Indication Type
10.3.5 Asia-Pacific Pneumonia Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Pneumonia Therapeutics Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Pneumonia Therapeutics Market
10.3.6.1.1 Australia Pneumonia Therapeutics Market by Product
10.3.6.1.2 Australia Pneumonia Therapeutics Market by Indication Type
10.3.6.1.3 Australia Pneumonia Therapeutics Market by Distribution Channel
10.3.6.2 China Pneumonia Therapeutics Market
10.3.6.2.1 China Pneumonia Therapeutics Market by Product
10.3.6.2.2 China Pneumonia Therapeutics Market by Indication Type
10.3.6.2.3 China Pneumonia Therapeutics Market by Distribution Channel
10.3.6.3 India Pneumonia Therapeutics Market
10.3.6.3.1 India Pneumonia Therapeutics Market by Product
10.3.6.3.2 India Pneumonia Therapeutics Market by Indication Type
10.3.6.3.3 India Pneumonia Therapeutics Market by Distribution Channel
10.3.6.4 Japan Pneumonia Therapeutics Market
10.3.6.4.1 Japan Pneumonia Therapeutics Market by Product
10.3.6.4.2 Japan Pneumonia Therapeutics Market by Indication Type
10.3.6.4.3 Japan Pneumonia Therapeutics Market by Distribution Channel
10.3.6.5 South Korea Pneumonia Therapeutics Market
10.3.6.5.1 South Korea Pneumonia Therapeutics Market by Product
10.3.6.5.2 South Korea Pneumonia Therapeutics Market by Indication Type
10.3.6.5.3 South Korea Pneumonia Therapeutics Market by Distribution Channel
10.3.6.6 Rest of Asia-Pacific Pneumonia Therapeutics Market
10.3.6.6.1 Rest of Asia-Pacific Pneumonia Therapeutics Market by Product
10.3.6.6.2 Rest of Asia-Pacific Pneumonia Therapeutics Market by Indication Type
10.3.6.6.3 Rest of Asia-Pacific Pneumonia Therapeutics Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Pneumonia Therapeutics Market Overview
10.4.2 Middle East and Africa Pneumonia Therapeutics Market Forecasts and Analysis
10.4.3 Middle East and Africa Pneumonia Therapeutics Market Forecasts and Analysis - By Product
10.4.4 Middle East and Africa Pneumonia Therapeutics Market Forecasts and Analysis - By Indication Type
10.4.5 Middle East and Africa Pneumonia Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Pneumonia Therapeutics Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Pneumonia Therapeutics Market
10.4.6.1.1 South Africa Pneumonia Therapeutics Market by Product
10.4.6.1.2 South Africa Pneumonia Therapeutics Market by Indication Type
10.4.6.1.3 South Africa Pneumonia Therapeutics Market by Distribution Channel
10.4.6.2 Saudi Arabia Pneumonia Therapeutics Market
10.4.6.2.1 Saudi Arabia Pneumonia Therapeutics Market by Product
10.4.6.2.2 Saudi Arabia Pneumonia Therapeutics Market by Indication Type
10.4.6.2.3 Saudi Arabia Pneumonia Therapeutics Market by Distribution Channel
10.4.6.3 U.A.E Pneumonia Therapeutics Market
10.4.6.3.1 U.A.E Pneumonia Therapeutics Market by Product
10.4.6.3.2 U.A.E Pneumonia Therapeutics Market by Indication Type
10.4.6.3.3 U.A.E Pneumonia Therapeutics Market by Distribution Channel
10.4.6.4 Rest of Middle East and Africa Pneumonia Therapeutics Market
10.4.6.4.1 Rest of Middle East and Africa Pneumonia Therapeutics Market by Product
10.4.6.4.2 Rest of Middle East and Africa Pneumonia Therapeutics Market by Indication Type
10.4.6.4.3 Rest of Middle East and Africa Pneumonia Therapeutics Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Pneumonia Therapeutics Market Overview
10.5.2 South and Central America Pneumonia Therapeutics Market Forecasts and Analysis
10.5.3 South and Central America Pneumonia Therapeutics Market Forecasts and Analysis - By Product
10.5.4 South and Central America Pneumonia Therapeutics Market Forecasts and Analysis - By Indication Type
10.5.5 South and Central America Pneumonia Therapeutics Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Pneumonia Therapeutics Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Pneumonia Therapeutics Market
10.5.6.1.1 Brazil Pneumonia Therapeutics Market by Product
10.5.6.1.2 Brazil Pneumonia Therapeutics Market by Indication Type
10.5.6.1.3 Brazil Pneumonia Therapeutics Market by Distribution Channel
10.5.6.2 Argentina Pneumonia Therapeutics Market
10.5.6.2.1 Argentina Pneumonia Therapeutics Market by Product
10.5.6.2.2 Argentina Pneumonia Therapeutics Market by Indication Type
10.5.6.2.3 Argentina Pneumonia Therapeutics Market by Distribution Channel
10.5.6.3 Rest of South and Central America Pneumonia Therapeutics Market
10.5.6.3.1 Rest of South and Central America Pneumonia Therapeutics Market by Product
10.5.6.3.2 Rest of South and Central America Pneumonia Therapeutics Market by Indication Type
10.5.6.3.3 Rest of South and Central America Pneumonia Therapeutics Market by Distribution Channel
11. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PNEUMONIA THERAPEUTICS MARKET
11.1 North America
11.2 Europe
11.3 Asia-Pacific
11.4 Middle East and Africa
11.5 South and Central America
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. PNEUMONIA THERAPEUTICS MARKET, KEY COMPANY PROFILES
13.1. PFIZER, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. MERCK AND CO., INC.
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. GLAXOSMITHKLINE PLC
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. BAYER AG
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. NOVARTIS AG
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ALLERGAN
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. LUPIN PHARMACEUTICALS, INC.
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. SMITH AND NEPHEW
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ABBOTT
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. CIPLA
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. Pfizer, Inc.
2. Merck & Co., Inc.
3. GlaxoSmithKline Plc
4. Bayer AG
5. Novartis AG
6. Allergan
7. Lupin Pharmaceuticals, Inc.
8. Smith & Nephew
9. Abbott
10. Cipla
11. Mylan
12. Sanofi
13. AstraZeneca
14. Biotest
15. Tetraphase Pharmaceuticals
TIPRE00021595
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking